Pelthos Therapeutics (PTHS) Cash from Financing Activities (2023 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Cash from Financing Activities of $18.0 million for Q4 2025, up 25126.39% year-over-year from N/an in Q4 2024, and down 32.49% quarter-over-quarter from $26.7 million in Q3 2025.
Pelthos Therapeutics (PTHS) Cash from Financing Activities (2023 - 2026) Analysis & Trends
Pelthos Therapeutics' Cash from Financing Activities history runs 3 years deep, the most recent figure standing at $18.0 million for Q4 2025.
- In Q4 2025, Cash from Financing Activities rose 25126.39% year-over-year to $18.0 million; the TTM figure through Dec 2025 stood at $45.3 million (up 630.17% YoY), while the FY2025 annual figure was $45.3 million, up 630.17% from the prior year.
- Cash from Financing Activities for Q4 2025 stood at $18.0 million, down from $26.7 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $26.7 million in Q3 2025, with the low at -$972015.0 in Q3 2024.
- The 3-year median for Cash from Financing Activities is $312500.0 (2025), against an average of $4.4 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities slumped 590.6% in 2024, then jumped 25126.39% in 2025.
- Pelthos Therapeutics' Cash from Financing Activities stood at $430412.0 in 2023, then plunged by 116.73% to -$72000.0 in 2024, then surged by 25126.39% to $18.0 million in 2025.
- Business Quant data shows PTHS's Cash from Financing Activities at $18.0 million in Q4 2025, $26.7 million in Q3 2025, and $375000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 14.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -6.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 36.24 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -16.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 27.18 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -273.15 Mn |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn | 27.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.52 Mn |
| Jun 30, 2026 | 27.52 Mn |
| Dec 31, 2025 | 18.02 Mn |
| Dec 31, 2025 | 18.02 Mn |
| Sep 30, 2025 | 26.69 Mn |
| Sep 30, 2025 | 26.69 Mn |
| Jun 30, 2025 | 375,000.00 |
| Jun 30, 2025 | 375,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | -972,015.00 |
| Sep 30, 2024 | -972,015.00 |
| Jun 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 5.67 Mn |
| Mar 31, 2024 | 5.67 Mn |
| Dec 31, 2023 | 430,412.00 |
| Dec 31, 2023 | 430,412.00 |